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Summary Therapeutic drug monitoring (TDM) has declined with newer anti-epi-
leptic drugs (AEDs) having no therapeutic window. Use of unbound (free) fraction has
almost completely disappeared. The case reported highlights its importance and
offers sound reason for its retention.
A 66-year-old Caucasian man with known epilepsy was admitted with vomiting,
ataxia and nystagmus presumably due to AED toxicity. Medications included valproate
(VPA) 1 g bd; phenytoin (PHT) 200 mg tds; carbamazepine (CBZ) 400 mgmane, 200 mg
midi, 400 mg nocte; levetiracetam (LEV) 250 mg bd. Initial AED-TDM revealed total
serum levels of CBZ: 27 mmol/L; PHT: 37 mmol/L; VPA 499 mmol/L, therapeutic or
subtherapeutic. Free levels were subsequently measured demonstrating CBZ:
8.2 mmol/L; PHT: 5 mmol/L; VPA 93 mmol/L. Consequently, VPA was initially omitted
and dosage reduced with cessation of toxicity. AED regimen was greatly simplified and
remained efficacious.
This case highlights the value of TDM with polypharmacy and suggested AED
toxicity. Total AED levels failed to identify the cause, which the unbound, free
fraction identified. While total PHTwas borderline subtherapeutic (37 mmol/L; range:
40—80) the free level was therapeutic (5 mmol/L; range: 4—8) and while VPA was
therapeutic (VPA 499 mmol/L; range: 300—750) the free level was supratherapeutic
(93 mmol/L; range: 30—75). Acknowledgement of discordance between total and free
levels for highly protein-bound AED is highlighted.
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The use of therapeutic drug monitoring (TDM) of
anti-epileptic drugs (AEDs) in the treatment of epi-
lepsy, starting with phenytoin (PHT), has been
recognised for almost 50 years.1 By the 1970s, the
use of total drug level monitoring was widely
accepted as adjunctive tomanipulatingmedications
in the management of epilepsy,2 based on the. Published by Elsevier Ltd. All rights reserved.
Value of TDM and unbound (free) levels 573expectation that the concentration of AED within
plasma reflected therapeutic efficacy.3
The relevance of the free or unbound fraction of
the AED PHT was recognised in 1960.4 The role of
total and free AED serum concentrations was further
investigated in the mid-1980s5 demonstrating that
there existed a 30% discordance between the total
and free AED level results for PHT and valproate
(VPA) (known to be 90% protein bound and 10% free
under normal circumstances) and a 20% discordance
between total and free drug levels for carbamaze-
pine (CBZ) (known to be approximately 75% protein
bound and 25% free under normal circumstances).5
More recently, the cost effectiveness and appro-
priateness of the use of TDM has been questioned,6,7
particularly with the newer AEDs where it has been
shown that such monitoring need not correlate with
efficacy.7—10
The following case reports the use of discordant
free fraction measurement of AED in determining
the appropriate medication to be altered in order to
achieve optimal patient care and reviews the role of
total and free AED level measurement in the treat-
ment of epilepsy.Case report
S.M., a 66-year-old Caucasian man with known
epilepsy, ischaemic heart disease, hypertension,
hyperlipidaemia, oesophageal reflux and hearing
loss presented to the Emergency Department with
vomiting, diarrhoea, and unsteady gait. His epi-
lepsy was controlled with PHT 200 mg tds; VPA 1 g
bd; CBZ 400 mg mane, 200 mg midi, 400 mg nocte;
and levetiracetam (LEV) 250 mg bd. Other medica-
tions included aspirin 100 mg daily; clopidogrel
75 mg midi; simvastatin 40 mg nocte; metoprolol
100 mg bd; perindopril 8 mg mane; amlodipine
10 mg mane; frusemide 40 mg mane; and spirono-
lactone 25 mg mane. On examination he was found
to have bilateral horizontal nystagmus and signifi-
cant ataxia.
The clinical picture was diagnosed as consistent
with AED toxicity, however, total serum AED levels
were measured which demonstrated sub-therapeu-
tic PHT (37 mmol/L; range: 40—80), and therapeutic
CBZ (27 mmol/L; range: 25—50) and VPA (499 mmol/
L; range: 300—750). LEV levels were unavailable
within the hospital due to non-existence of an
accepted therapeutic window. These results contra-
dicted the diagnosis of AED toxicity, despite his
clinical presentation and the absence of a viable
alternative diagnosis.
The treating neurologist requested measure-
ment of free AED levels to clarify the cause ofhis suspected toxicity, a request that was met
with significant resistance from the laboratory
responsible for measuring same. Following discus-
sions free levels were measured and revealed
a supra-therapeutic level of free VPA (93 mmol/
L; range: 30—75); and therapeutic levels of free
PHT (5 mmol/L; range: 4—8) and free CBZ
(8.2 mmol/L; range: 6—13). On the basis of these
findings and the presenting symptoms being typical
side effects of VPA, VPA was considered the
most likely cause of S.M.’s toxicity and was
initially omitted for one day and then reintroduced
at a reduced dosage of 500 mg bd. This led to
the prompt cessation of his symptoms. Over the
subsequent days, in order to reduce the complex-
ity of his antiepileptic regimen and reduce the
potential for drug interactions, PHT and LEV were
withdrawn while the administration of CBZ was
simplified to 400 mg mane and 600 mg nocte. S.M.
remained seizure free and was discharged home 6
days later with a much simplified AED regimen and
morning drug fasting blood samples revealing ther-
apeutic levels of VPA (total 351 mmol/L, free
31 mmol/L) and CBZ (total 30 mmol/L, free
8.2 mmol/L). S.M. was last seen 8 months post-
discharge and has not had another episode of AED
toxicity to this date.Discussion
While TDM has been used for decades in themanage-
ment of epilepsy,2,3,11 its use has been declining in
recent years.6,7,12 The basis for the reluctance of
the pathology department to offer further AED level
determination, in the case of S.M., was acknowl-
edgement of the recent literature which questioned
the relevance of TDM, particularly with reference to
free fraction determination.7,9,10,13—16 Free frac-
tion determination has never been as widely
adopted, as has total serum AED level determina-
tion,17—19 and the fact that S.M.’s total AED levels
were either within the mid-to-low therapeutic
range (regarding VPA and CBZ) or in the sub-ther-
apeutic domain (as was the case with PHT) was
proffered as the rationale for the initial refusal to
perform free fraction determination. It was
accepted that there was no agreed therapeutic
window for, nor capacity to measure, LEV levels
in the hospital but the dosage of same, at 250 mg
twice daily, was thought to be so low as to make it an
unlikely cause of the toxicity, recognising that the
mean dosage of LEV was 3000 mg in pivotal clinical
trials.20 The pathology service failed to acknowl-
edge the potential discordance between total and
free levels of AED, with complete reliance on total
574 K. Chan, R.G. Beranlevels which, in this case, failed to explain the
clinical picture.
With the introduction of newer AEDs, where
TDM has been show to be less beneficial,7,9,10 as
in the case of gabapentin, the decline in TDM has
been accelerated to the point that emerged in the
case of S.M. where the literature was used as the
basis for initial refusal to offer the service. As a
result of the current trends, many doctors, espe-
cially junior house staff, often do not understand
the clinical use and value of TDM and thus will be
less likely to request these tests, particularly
measurement of free levels, which proved invalu-
able in the management of the toxicity encoun-
tered by S.M.
This case highlights the value of TDM in the
setting of polypharmacy and clinical evidence of
AED toxicity. In such a situation there are complex
drug interactions, affecting both AED metabo-
lism21—23 and potential for protein binding17,23
which may make it impossible to identify which
of the AEDs is the cause of the patient’s symptoms.
S.M.’s case shows that, with therapeutic or sub-
therapeutic total AED levels, they can fail to
identify the cause of toxicity, in which setting
the measurement of the free, or unbound, frac-
tions may be invaluable to identify the causative
AED, namely VPA which showed a mid-range ther-
apeutic total level of 499 mmol/L but a supra-
therapeutic free level of 93 mmol/L. There are a
number of possible explanations for the elevated
valproate level in this case. Firstly valproate
demonstrates non-linear pharmacokinetics with
concentration dependent plasma protein binding.
If the protein binding sites are saturated, the free
valproate level can rise rapidly. Secondly, there
are a number of drug interactions in play. Valpro-
ate and phenytoin may displace each other from
protein binding sites, while aspirin also has this
property as well as inhibiting the metabolism of
valproate.
The potential discordance between total and free
AED levels5 underlines the value of measuring the
free fraction levels in certain circumstances of TDM,
as evidenced in the present case. This discordance,
between total and free AED TDM, has been demon-
strated previously, however, with the decline in use
of TDM it is less well recognised by junior doctors
and was therefore difficult to organise in the case of
S.M. where its relevance was confirmed and greatly
assisted patient care.
This case serves as a reminder that TDM, and in
particular free AED level determination, has a valu-
able role in the clinical management of epilepsy, if
used judiciously in circumstances where it may be
the only means to identify which, of a variety ofAEDs, is responsible for a particular clinical presen-
tation.Conflicts of interest
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